# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 61-70 of 2194 results.
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
Status: Terminated
Last Changed: Apr 27, 2018
First Received: May 21, 2009
Disease(s): B-cell Lymphoma
Intervention(s): 90Y-DOTA-hLL2
Locations: Chu/Clcc Nantes, Nantes, France
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
Status: Recruiting
Last Changed: Aug 04, 2020
First Received: Oct 12, 2018
Disease(s): Refractory Large B-cell Lymphoma
Intervention(s): Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Locations: Stanford Cancer Institute, Palo Alto, California, United States
UCLA Hematology/ Oncology, Santa Monica, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 2 other locations.
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jul 31, 2020
First Received: Jun 28, 2019
Disease(s): Refractory Large B-cell Lymphoma
Intervention(s): Axicabtagene Ciloleucel, Rituximab, Lenalidomide, Fludarabine, Cyclophosphamide
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope National Medical Center, Duarte, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
UCLA Hematology/Oncology, Santa Monica, California, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
... and 8 other locations.
CART-19 Cells for R/R B-cell Lymphoma
Status: Recruiting
Last Changed: Jan 05, 2018
First Received: Jan 05, 2018
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): CART-19 cells
Locations: Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Status: Completed
Last Changed: Nov 22, 2017
First Received: Jun 22, 2012
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Bendamustine, Ofatumumab
Locations: Florida Cancer Specialists-South, Fort Myers, Florida, United States
Woodlands Medical Specialists, Pensacola, Florida, United States
Florida Cancer Specialists North, Saint Petersburg, Florida, United States
Space Coast Cancer Center, Titusville, Florida, United States
Providence Medical Group, Terre Haute, Indiana, United States
... and 7 other locations.
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status: Completed
Last Changed: May 30, 2017
First Received: May 15, 2013
Disease(s): CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Intervention(s): AEB071, Everolimus
Locations: Washington University School of Medicine Dept of Oncology., Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center Onc. Dept., New York, New York, United States
Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States
Novartis Investigative Site, Rouen Cedex 1, France
Novartis Investigative Site, Mainz, Germany
... and 11 other locations.
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Status: Terminated
Last Changed: Jan 07, 2015
First Received: Jul 26, 2011
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): AEB071
Locations: City of Hope National Medical Center, Duarte, California, United States
Washington University School of Medicine Div. of Medical Oncology, St. Louis, Missouri, United States
Hackensack University Medical Center Hackensack (SC), Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center MSK 2, New York, New York, United States
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, United States
... and 20 other locations.
CNS Prophylaxis in Diffuse Large B-cell Lymphoma
Status: Unknown status
Last Changed: Jun 06, 2016
First Received: May 19, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Methotrexate
Locations: University Hospital Brno-Bohunice, Brno, Czech Republic
University Hospital Hradec Králové, Hradec Králové, Czech Republic
University Hospital Ostrava, Ostrava, Czech Republic
University Hospital Pilsen, Pilsen, Czech Republic
University Hospital Kralovske Vinohrady, Prague, Czech Republic
... and 2 other locations.
Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma
Status: Completed
Last Changed: Mar 03, 2015
First Received: Sep 15, 2010
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): CSF analysis
Locations: Samsung Medical Center, Seoul, Korea, Republic of
Asan Medical Center, Seoul, Korea, Republic of
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Aug 14, 2019
First Received: Aug 14, 2019
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): Recombinant Anti-CD19m-CD3 Antibody Injection